Study of the setpoint system after approval
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study is checking how well the SetPoint System works and how safe it is after it has been approved. It is for people who have already had the implant procedure attempted.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a candidate for the SetPoint System (your doctor has said it's right for you).
- You have already had the SetPoint System implant procedure attempted.
- You do not have any medical condition that would make the implant unsafe for you (no contraindications).
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who need knee replacement for “end-stage” knee osteoarthritis and will receive a specific knee implant system as part of routine care. It aims to measure how well the knee replacement works for patients over time, which may help improve future care.
This trial studies a specific shoulder replacement implant system. It may help people with damaged shoulder joints by testing how well the implant works and how it affects recovery and function.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
This study tests if a digital app called RheumaBuddy4.1 can help manage rheumatoid arthritis symptoms. You would use the app at home and report how you feel.
This study tests a new oral medication, PTC844, for people with active rheumatoid arthritis whose current treatments have not worked well enough or who haven't tried any yet. The goal is to see if it can reduce joint pain and swelling.
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.